Overview
- Reports say AstraZeneca has held talks about a roughly $400 billion merger with U.S. peer Bristol Myers Squibb but the discussions are unconfirmed and have not been announced by either company.
- If completed, the transaction would create one of the world’s largest drugmakers by combining the two firms’ market values and product portfolios.
- AstraZeneca has taken recent steps that increase its U.S. footprint, including upgrading its New York listing to equal status with London and agreeing reported U.S. investments and manufacturing commitments worth about $50 billion.
- The company insists it will remain headquartered in Cambridge and keep its London listing while critics note the deal would intensify scrutiny of jobs and research facilities in UK sites that employ roughly 10,000 people.
- The proposed talks revive political memory of Pfizer’s failed attempt to buy AstraZeneca a decade ago and analysts say any deal could face close regulatory and political review in both countries.